CPhI Japan to be held in Tokyo in March
Pharmaceutical ingredients event returns to its traditional timeslot
Events organiser UBM Live, a division of UBM Plc, announces that CPhI Japan will return to its traditional March timeslot in Tokyo for 2012. Last year the event was held on a smaller scale in Osaka to accommodate the aftermath of the Japan earthquakes.
After taking time to stabilise, Tokyo will once again play host to the pharmaceutical ingredients event, which runs from 21–23 March at the Tokyo Big Sight Exhibition Centre along with co-located events ICSE Japan for outsourcing solutions, P-MEC Japan for pharma machinery and technology, Pharmatec for drug packaging and delivery technology and the BioPh Pavilion for the biotechnology sector.
UBM Live expects the events to return to full scale with projections for more than 14,000 visitors and more than 450 specialised global industry suppliers featured.
There are both new and returning developments to the events line-up in Tokyo. The BioPh Pavilion has been expanded to showcase the latest materials, technologies and services for the development of biotech-based drugs.
A returning programme of sessions and workshops includes more than 120 conference and seminar sessions being held onsite over the three days.
‘It is an important time for the pharma portfolio to return to Tokyo at full scale. Japan is focused on future growth and the events offer an unparalleled opportunity to network within this expanding Pharma market,’ said Greg Kerwin, Pharma Portfolio Director.
He further noted: ‘The Japan Pharma events have closely mirrored the developments in this market through their own steady growth. The Japanese government has been investing in infrastructure development, such as bioindustrial cluster projects and supporting programmes, in order to boost the sector. As Japanese pharma manufacturers are catching up with their competitors in the US and Europe within the bio field, the country is projected to continue gaining importance as key player in the global pharma industry.’
The generics sector is one area of the pharma market that is experiencing significant growth in Japan. Generics are expected to increase their market share through sales from 8.3% in 2010 to 12.8% in 2015. This is an increase of more than 50% in five years and the total generics market in Japan is predicted to be worth US$12.3bn also by 2015.